These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28285798)

  • 1. Corrigendum to "Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model" [Int. J. Cardiol. 227 (2017) 467-473].
    Tenekecioglu E; Torii R; Bourantas C; Abdelghani M; Cavalcante R; Sotomi Y; Crake T; Su S; Santoso T; Onuma Y; Serruys PW
    Int J Cardiol; 2017 May; 235():206. PubMed ID: 28285798
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model.
    Tenekecioglu E; Torii R; Bourantas C; Abdelghani M; Cavalcante R; Sotomi Y; Crake T; Su S; Santoso T; Onuma Y; Serruys PW
    Int J Cardiol; 2017 Jan; 227():467-473. PubMed ID: 27839816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Prognostic Impact of Interleukin-1 Receptor Antagonist in Patients with documented Coronary Artery Disease" [Int. J. Cardiol. 257 (2018) 24-29].
    Schofer N; Ludwig S; Rübsamen N; Schnabel R; Lackner KJ; Ruprecht HJ; Bickel C; Landmesser U; Blankenberg S; Zeller T
    Int J Cardiol; 2018 Jun; 261():239. PubMed ID: 29573812
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study" [Int. J. Cardiol. 215 (2016) 209-213].
    He M; Liu B; Sun D; Pan Y; Zheng W; Shi J; Zhao S; Dong X; Lu S; Li M; Han Y; Li Y
    Int J Cardiol; 2017 Jan; 227():956. PubMed ID: 27863938
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "Contrast media use in patients with chronic kidney disease undergoing coronary angiography: A systematic review and meta-analysis of randomized trials" [Int. J. Cardiol. (2017) 137-144].
    Pandya B; Chalhoub JM; Parikh V; Gaddam S; Spagnola J; El-Sayegh S; Bogin M; Kandov R; Lafferty J; Bangalore S
    Int J Cardiol; 2017 May; 235():205. PubMed ID: 28291624
    [No Abstract]   [Full Text] [Related]  

  • 8. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Gender differences in the management of acute coronary syndrome patients: One year results from HPIAR (HP -India ACS Registry)" [Int. J. Cardiol. 248 (2017) 1-6].
    Mahajan K; Negi PC; Merwaha R; Mahajan N; Chauhan V; Asotra S
    Int J Cardiol; 2018 Feb; 253():197. PubMed ID: 29306464
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Comparison of transport methods for patients with ST-elevation myocardial infarction to a percutaneous coronary intervention center and determination of factors influencing long-term mortality" [Int. J. Cardiol. 202 (2016) 135-137].
    Stachowiak P; Wójcik G; Kazimierczak A; Clark J; Gorący J; Kornacewicz-Jach Z
    Int J Cardiol; 2016 Jul; 214():537. PubMed ID: 27117046
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum to "Epidemiology of lower extremity artery disease in a rural setting in Benin, West Africa: the TAHES study" [Int. J. Cardiol. 267 (2018) 198-201].
    Amidou SA; Houehanou YC; Houinato SD; Aboyans V; Sonou A; Saka D; Houinato M; Desormais I; Magne J; Houenassi MD; Preux PM; Lacroix P;
    Int J Cardiol; 2018 Nov; 271():406. PubMed ID: 29983249
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials" [Int. J. Cardiol. 205 (2016) 89-96].
    Liu J; Fan M; Zhao J; Zhao B; Zhang C; Liu C; Dong Y
    Int J Cardiol; 2018 Nov; 271():408. PubMed ID: 29925473
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Letter to correlation between pulmonary artery pressure and thoracic impedance: Insights from dailymonitoring through an implanted device in chronic heart failure" [Int. J. Cardiol. 245 (2017) 196-200].
    Gronda E; Sacchi S; Vanoli E
    Int J Cardiol; 2018 Nov; 271():404. PubMed ID: 30025652
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
    Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
    EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of five coronary devices on plaque size: insights from the ABSORB and SPIRIT trials.
    García-García HM; Serruys PW; Campos CM; Onuma Y
    Int J Cardiol; 2014 Aug; 175(3):441-5. PubMed ID: 25017907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
    Gomez-Lara J; Brugaletta S; Farooq V; van Geuns RJ; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Morel MA; Dorange C; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):789-99. PubMed ID: 21777888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.